|
Blood-lead concentrations range (μg/L)
|
Bmed
|
Bsocietal
|
Total benefits
|
Hypothetical threshold values (μg/L)
|
Total cumulated benefits
|
|---|
|
15 ≤ B-Pb < 24
|
0.198
|
11.8
|
11.99 (1)
|
B-Pb ≥ 15
|
22.72 (1+2+3)
|
|
24 ≤ B-Pb < 100
|
0.083
|
10.2
|
10.28 (2)
|
B-Pb ≥ 24
|
10.72 (2+3)
|
|
B-Pb ≥ 100
|
0.016
|
0.44
|
0.44 (3)
|
B-Pb ≥ 100
|
0.44
|
- Table 4 shows the estimated total benefits ranged from blood-lead concentrations and total cumulated benefits based on three hypothetical values per year. We first differenced the estimated medical benefits (Bmed) and the societal benefits (Bsocietal) ranged from blood-lead concentrations:
- The 15-24 μg/L Bmed, the 24-100 μg/L Bmed and the ≥ 100 μg/L Bmed are the Bscreening15-24 (€0.198 Billion), the Bscreening24-100 (€0.083 billion) and the Btreatment≥ 100 (€0.016 billion), respectively.
- The 15-24 μg/L Bsocietal, the 24-100 μg/L Bsocietal and the ≥ 100 μg/L Bsocietal are the Bearn15-24 discounted (€11.8 billions), The Bearn24-100 discounted (€ 10.2 billions) and the Bearn≥ 100 discounted added to the Bspec.ed≥ 100 , the Bcrime≥ 100 and the Bother≥ 100 (€0.44 billion), respectively. The Bspec.ed≥ 100 equal to €0.01453 billion [(10% of the French population of children 3-6 years) ((79.8%*38,958) + (20.1%*48,255))], the Bcrime≥ 100 equal to € 0.0618 billion and the Bother≥ 100 equal to €0.0427 billion, which are the intangible avoided costs. We estimated the total benefits (Bmed +Bsocietal) ranged from blood-lead concentrations: €11.99 billions (1), €10,28 billions (2) and € 0.44 billion (3).
- We secondly estimated total cumulated benefits per year based on the three hypothetical threshold values, above 15, 24 and 100 μg/L. We obtained €22.72 billions (1+2+3), €10.72 billions (2+3) and € 0.44 billion (3), respectively.
